210 related articles for article (PubMed ID: 22994199)
21. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
[TBL] [Abstract][Full Text] [Related]
22. Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications.
Gloghini A; Bosco A; Ponzoni M; Spina M; Carbone A
Expert Rev Hematol; 2015 Apr; 8(2):217-23. PubMed ID: 25487651
[TBL] [Abstract][Full Text] [Related]
23. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Spinner MA; Varma G; Advani RH
Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
[TBL] [Abstract][Full Text] [Related]
24. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
Karube K; Niino D; Kimura Y; Ohshima K
Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
[TBL] [Abstract][Full Text] [Related]
25. Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma.
McKay P; Fielding P; Gallop-Evans E; Hall GW; Lambert J; Leach M; Marafioti T; McNamara C;
Br J Haematol; 2016 Jan; 172(1):32-43. PubMed ID: 26538004
[No Abstract] [Full Text] [Related]
26. Lymphocyte-predominant Hodgkin disease: a comprehensive overview.
Bose S; Ganesan C; Pant M; Lai C; Tabbara IA
Am J Clin Oncol; 2013 Feb; 36(1):91-6. PubMed ID: 21358294
[TBL] [Abstract][Full Text] [Related]
27. Nodular lymphocyte-predominant Hodgkin lymphoma.
Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
[TBL] [Abstract][Full Text] [Related]
28. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma.
Hartmann S; Eichenauer DA
Pathology; 2020 Jan; 52(1):142-153. PubMed ID: 31785822
[TBL] [Abstract][Full Text] [Related]
29. Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida.
Chera BS; Olivier K; Morris CG; Lynch JW; Mendenhall NP
Am J Clin Oncol; 2007 Dec; 30(6):601-6. PubMed ID: 18091054
[TBL] [Abstract][Full Text] [Related]
30. Management of Hodgkin lymphoma.
Ansell SM; Armitage JO
Mayo Clin Proc; 2006 Mar; 81(3):419-26. PubMed ID: 16529147
[TBL] [Abstract][Full Text] [Related]
31. The treatment of childhood Hodgkin lymphoma: improved survival in a developing country.
Büyükpamukçu M; Varan A; Akyüz C; Atahan L; Ozyar E; Kale G; Köksal Y; Kutluk T
Acta Oncol; 2009; 48(1):44-51. PubMed ID: 18777215
[TBL] [Abstract][Full Text] [Related]
32. How I treat nodular lymphocyte predominant Hodgkin lymphoma.
Advani RH; Hoppe RT
Blood; 2013 Dec; 122(26):4182-8. PubMed ID: 24215035
[TBL] [Abstract][Full Text] [Related]
33. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report.
Shankar A; Hall GW; Gorde-Grosjean S; Hasenclever D; Leblanc T; Hayward J; Lambilliotte A; Daw S; Perel Y; McCarthy K; Lejars O; Coulomb A; Oberlin WO; Wallace WH; Landman-Parker J
Eur J Cancer; 2012 Jul; 48(11):1700-6. PubMed ID: 22093944
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
Eichenauer DA; Fuchs M
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444420
[TBL] [Abstract][Full Text] [Related]
35. Nodular lymphocyte predominant Hodgkin's lymphoma.
Siddiqui N; Al-Diab AI
Saudi Med J; 2005 Feb; 26(2):241-5. PubMed ID: 15770298
[TBL] [Abstract][Full Text] [Related]
36. SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley MS; Advani RH
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):471-476. PubMed ID: 37076366
[TBL] [Abstract][Full Text] [Related]
37. Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India.
Prasad M; Narula G; Chinnaswamy G; Arora B; Shet T; Panjwani P; Sengar M; Laskar S; Khanna N; Banavali S
Pediatr Blood Cancer; 2018 Oct; 65(10):e27288. PubMed ID: 29893471
[TBL] [Abstract][Full Text] [Related]
38. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group.
Mauz-Körholz C; Lange T; Hasenclever D; Burkhardt B; Feller AC; Dörffel W; Kluge R; Vordermark D; Körholz D
Klin Padiatr; 2015 Nov; 227(6-7):314-21. PubMed ID: 26356319
[TBL] [Abstract][Full Text] [Related]
39. Nodular lymphocyte predominant Hodgkin lymphoma: Experience of Polish Pediatric Leukemia/Lymphoma Study Group.
Klekawka T; Balwierz W; Brozyna A; Chaber R; Dadela-Urbanek A; Koltan A; Kwasnicka J; Mitura-Lesiuk M; Muszynska-Roslan K; Przybyszewski B; Ruranska I; Smalisz K; Mizia-Malarz A; Stachowicz-Stencel T; Stolarska M; Wziatek A; Zielezinska K; Skoczen S
Pediatr Hematol Oncol; 2021 Oct; 38(7):609-619. PubMed ID: 33734010
[TBL] [Abstract][Full Text] [Related]
40. Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis.
Churchill HR; Roncador G; Warnke RA; Natkunam Y
Hum Pathol; 2010 Dec; 41(12):1726-34. PubMed ID: 20825974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
